Clarivate Plc reports developments in data, analytics and workflow software for academia and government, intellectual property, and life sciences and healthcare. Its news commonly covers earnings, subscription and recurring revenue trends, cash flow and leverage actions, and progress under its operating improvement initiatives.
Company updates also focus on AI-enabled research and decision-support products, including Web of Science Research Intelligence, Nexus Connect, Cortellis Regulatory Intelligence, Derwent-based patent analytics and other Clarivate data assets. Recurring announcements address institutional research intelligence, academic library workflows, regulatory intelligence for life sciences teams, intellectual property benchmarks and investor conference appearances.
Clarivate launched a report on the Unitary Patent Court's (UPC) first year of litigation activity. The analysis, based on Darts-ip data, showed consistent monthly infringement filings averaging ten per month. The number of UPC decisions rose 155% in the second half compared to the first half. German divisions dominated infringement cases, with Munich accounting for 37.7%. Six of the top ten plaintiffs were U.S.-based, and major representative firms handled 71.3% of cases. Electrical engineering led in infringement cases with 39.8%, while instruments led in revocation cases at 36%. The ICT industry saw 38.5% of patents asserted before the UPC.
Clarivate has released its MedTech Trends to Watch 2024 report, announcing key trends and challenges in the MedTech sector. Highlighting economic uncertainty, regulatory changes, and supply chain issues, the report also identifies opportunities in AI integration, ambulatory surgical centers, and advancements in technologies like pulsed-field ablation and surgical robotics. The shift from inpatient to outpatient settings for procedures and the impact of GLP-1 receptor agonists are significant. Macro trends such as an aging population and increased healthcare access are driving further innovation and investment. Regulatory changes in Mainland China and supply chain resilience are important areas of focus. The report is based on insights from over 40 analysts covering 80 markets in more than 50 countries.
Clarivate (NYSE: CLVT) released a Global Research Report highlighting the rapid growth in digital health research and innovation. The report, developed by the Institute for Scientific Information (ISI) and the Clarivate Center for IP and Innovation Research, analyzes data from multiple Clarivate portfolios. It reveals a 70-fold increase in digital health academic publications from 2012 to 2022 and identifies nearly 140,000 patent inventions from 2013 to 2022. Key players in the field include organizations like Snap, AstraZeneca, and the Chinese Academy of Sciences. The advancements in AI and digital technologies, such as mobile apps and telemedicine, are driving this growth, improving healthcare delivery and reducing costs. The study builds on initial findings presented at Digital Health 2024 held at Stanford University.
Clarivate Plc (NYSE: CLVT) unveiled the IP Collaboration Hub™ at the 2024 Clarivate Ignite conference in San Diego. This new solution integrates with Clarivate's IP management systems (IPMS), providing a central hub for collaboration with local agents globally. It aims to streamline IP filing and prosecution by automating and standardizing communication management. The hub mitigates risks associated with email reliance and improves efficiency by automatically docketing communications in the IPMS. This launch aligns with Clarivate's strategy to enhance IP lifecycle support and maintain leadership in patent maintenance and IP management software.
Clarivate, a leading provider of transformative intelligence, has released the 2024 update to the Journal Citation Reports (JCR). This update features a comprehensive ranking of high-quality journals, incorporating the Emerging Sources Citation Index (ESCI) for a more unified category view. The JCR now includes 21,800 journals, with 544 receiving their Journal Impact Factor (JIF) for the first time.
Significant enhancements include integrated rankings across subject categories, eliminating separate JIF rankings for journals indexed in multiple editions. This change unifies the rankings of journals across fields such as psychiatry. The update aims to support research integrity and level the global playing field by valuing all trustworthy journals uniformly.
The 2024 release recognizes scholarly journals from 113 countries across 254 categories, offering a more complete user experience with enriched data, metrics, and analysis.
Clarivate has released its 2024 Companies to Watch report, spotlighting seven innovators in antibody-drug conjugates (ADCs) set to revolutionize cancer treatment. The report highlights companies like Adcendo, Araris Biotech, GO Therapeutics, Heidelberg Pharma, Pheon Therapeutics, Tallac Therapeutics, and Tubulis, which are advancing ADC technology to provide targeted cancer therapies with fewer side effects. Major pharmaceutical companies are keen on integrating ADCs into their portfolios. The number of ADCs on the market has surged in the past five years, reflecting their growing impact. Despite historical challenges in ADC development, new approaches are overcoming these barriers, positioning ADCs as a cornerstone in modern oncology.
Clarivate (NYSE: CLVT) has launched Research Horizon Navigator, an AI-native module within InCites Benchmarking & Analytics, designed to identify emerging research topics and future breakthrough areas. Utilizing data from the Web of Science Core Collection and a novel methodology by the Institute for Scientific Information, the tool highlights new research trends and provides insights for strategic investments. Research Horizon Navigator, available to InCites subscribers, offers interactive visualizations and identifies key contributors. Applications include technology watch, collaboration, funding program management, and research assessment, with continuous enhancements based on community feedback.
Clarivate has partnered with HealthWise Data to integrate Social Determinants of Health (SDoH) attributes into its Real-World Data (RWD) repository. This collaboration aims to enhance patient insights and address healthcare equity by incorporating factors like income, education, and ethnicity. The integration will provide healthcare professionals with comprehensive data to improve patient outcomes and public health interventions.
Bob Morrison, VP of RWD Data Strategy and Operations at Clarivate, emphasizes the milestone's significance in delivering transformative insights. Anne Smith, CEO of HealthWise Data, highlights the improved patient view and outcomes resulting from the partnership. The enhanced RWD is expected to aid in identifying at-risk populations and facilitating targeted early prevention measures.
Clarivate announced the automatic conversion of its 5.25% Series A Mandatory Convertible Preferred Shares into ordinary shares on June 3, 2024. Shareholders will receive 3.8462 ordinary shares per Preferred Share, with cash paid for fractional shares. A final quarterly cash dividend of $1.3125 per Preferred Share will be distributed to holders of record as of May 15, 2024. This move aligns with Clarivate's strategy to simplify its capital structure.
Clarivate announces that 500 institutions, including Florida Atlantic University, have adopted its Rialto™ books marketplace solution. This highlights Rialto's rapid success in enhancing library collection management globally. The platform integrates with Alma, enabling real-time budget tracking and efficient resource ordering. Rialto offers features like AI-driven recommendations, a comprehensive marketplace, and seamless workflows to improve library operations.